KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Net Margin (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 15 years of Net Margin data on record, last reported at 384.04% in Q4 2025.

  • For Q4 2025, Net Margin rose 35914.0% year-over-year to 384.04%; the TTM value through Dec 2025 reached 124.72%, up 11497.0%, while the annual FY2025 figure was 124.72%, 11497.0% up from the prior year.
  • Net Margin reached 384.04% in Q4 2025 per RIGL's latest filing, up from 40.17% in the prior quarter.
  • Across five years, Net Margin topped out at 384.04% in Q4 2025 and bottomed at 164.0% in Q1 2022.
  • Average Net Margin over 5 years is 3.85%, with a median of 11.51% recorded in 2023.
  • Peak YoY movement for Net Margin: plummeted -21275bps in 2022, then surged 35914bps in 2025.
  • A 5-year view of Net Margin shows it stood at 110.74% in 2021, then skyrocketed by 102bps to 2.73% in 2022, then decreased by -25bps to 2.06% in 2023, then surged by 1109bps to 24.9% in 2024, then soared by 1442bps to 384.04% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 384.04% in Q4 2025, 40.17% in Q3 2025, and 58.63% in Q2 2025.